Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistryResearch in context
Summary: Background: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on lung function, nutritional status, pulmonary exacerbation freque...
Saved in:
Similar Items
-
Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
by: Wolfgang Gruber, et al.
Published: (2024) -
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
by: Margarete Olivier, et al.
Published: (2023) -
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
by: Patrick O. Hanafin, et al.
Published: (2021) -
Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study
by: Dorothea Appelt, et al.
Published: (2023) -
Exhaled aerosols among PCR-confirmed SARS-CoV-2-infected children
by: Pia Schuchmann, et al.
Published: (2023)